At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
Oral Topotecan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Trial of Oral Metronomic Topotecan in Combination With Oral Pazopanib Utilizing a Daily Dosing Schedule to Treat Recurrent or Persistent Gynecologic Tumors
In Brief
A Phase 1 clinical trial evaluating Oral Topotecan and Pazopanib for Gynecologic Tumors. Completed, enrolled 33 participants across 1 site.
Detailed Summary
This is a Phase 1, dose-escalation study in female patients with recurrent or persistent gynecologic tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGynecologic Tumors
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartApr 2009
Primary CompletionJun 2015
Study CompletionSep 2015
TodayJul 2026
First PostedDec 2, 2008
Enrollment StartApr 1, 2009
Primary CompletionJun 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 17.6 years ago
Interventions
Oral Topotecandrug
Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
Pazopanibdrug
Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.